The Marilyn Fagan Ovarian Cancer Patient Advocacy Program
Literature, news and videos pertinent to
The Marilyn Fagan Ovarian Cancer Patient Advocacy Program
The Operating Room of the Future – Video regarding the pathbreaking work of InSightec
based in Tirat Carmel, Israel, www.insightec.com
- FDA approves olaparib capsules (Lynparza, AstraZeneca Pharmaceuticals LP) as monotherapy for the treatment of patients
- Tiny capsule effectively kills cancer cells
- Life-Saving DNA Test Overlooked in Rise of Colon Cancer
- Epithelial Ovarian Cancer - Clinical Trials
- Primary Peritoneal Carcinoma - Clinical Trials
- Hospitals scramble on the front lines of drug shortages
- OVA1 more effective than CA 125 test in evaluating likelihood of ovarian cancer
- Nearly 25% of Women With Early Ovarian Cancer Not Given Recommended Biopsies
- ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
- BMJ Study On Ovarian Cancer Wins Prestigious Award
- Second Phase III Study Showed Avastin-Containing Regimen Helped Women With Ovarian Cancer Live Longer Without Their Disease Getting Worse
- Protein Inhibitor Revives Chemotherapy For Ovarian Patients: TGen Findings
Marilyn Fagan Ovarian Cancer Patient Advocacy Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
For more information about this special program, please click on...
Federal Tax I.D.: EIN 86-0818253